Want to see AU:1AD full AI Analyst Report?
1AD Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.02
Previous CloseN/A
Volume270.05K
Average Volume (3M)574.71K
Market Cap
AU$9.64M
Enterprise ValueAU$7.64
Total Cash (Recent Filing)AU$1.58M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding3,212,169,000
10 Day Avg. Volume957,709
30 Day Avg. Volume574,705
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)16.60
Price to Sales (P/S)0.00
P/FCF Ratio-1.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt EliminationEliminating debt reduces interest obligations and lender dependence, giving AdAlta greater financial flexibility while it develops its pipeline. However, the benefit is limited because the company still has weak cash generation and may require external funding.
Proprietary I-body PlatformA proprietary discovery platform can support multiple therapeutic programs and create reusable research capabilities across inflammatory and fibrotic diseases. This provides a potential strategic foundation beyond any single candidate, although commercial validation is not yet demonstrated.
High Historical Gross MarginsHigh gross margins on prior revenue suggest the underlying product or income model could have attractive economics once meaningful revenue returns. This may support future operating leverage, although the absence of FY2026 revenue means the benefit is currently unproven.
Bears Say
Revenue DeteriorationThe sustained decline to zero revenue indicates that AdAlta currently lacks a dependable commercial income stream. Without recurring product, licensing, or partnership revenue, funding for research and operations remains dependent on uncertain external capital.
Persistent Operating LossesRecurring operating losses show that the business has not yet reached commercial scale or self-sustaining profitability. Continued losses can consume capital needed for clinical development and increase the risk of future equity issuance or program reductions.
Cash Burn And Weak Funding RunwayPersistent operating and free-cash-flow deficits mean AdAlta cannot currently fund its activities internally. Ongoing cash burn, combined with materially reduced assets, increases dependence on fundraising and creates potential dilution or development delays.
AdAlta Ltd. News
1AD FAQ
What was AdAlta Ltd.’s price range in the past 12 months?
AdAlta Ltd. lowest share price was AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is AdAlta Ltd.’s market cap?
AdAlta Ltd.’s market cap is AU$9.64M.
When is AdAlta Ltd.’s upcoming earnings report date?
AdAlta Ltd.’s upcoming earnings report date is Feb 25, 2027 which is in 180 days.
How were AdAlta Ltd.’s earnings last quarter?
AdAlta Ltd. released its earnings results on Aug 21, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AdAlta Ltd. overvalued?
According to Wall Street analysts AdAlta Ltd.’s price is currently Overvalued.
Does AdAlta Ltd. pay dividends?
AdAlta Ltd. does not currently pay dividends.
What is AdAlta Ltd.’s EPS estimate?
AdAlta Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AdAlta Ltd. have?
AdAlta Ltd. has 3,212,169,000 shares outstanding.
What happened to AdAlta Ltd.’s price movement after its last earnings report?
AdAlta Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AdAlta Ltd.?
Currently, no hedge funds are holding shares in AU:1AD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AdAlta Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.61%
Trailing 12-Months
Company Description
AdAlta Ltd.
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other related fibrotic diseases. The company has forged strategic alliances, including a collaboration with GE Healthcare to identify i-bodies that bind to granzyme B, and a partnership with Carina Biotech Pty Ltd. focused on developing CAR-T cell products designed to target various solid tumor antigens. AdAlta Limited was founded in 2006 and is headquartered in Bundoora, Australia.
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Regeneus Ltd.
―
Recce Pharmaceuticals Ltd.
―